Rudolf Likar1, Markus Koestenberger1,2, Martin Stutschnig3, Gerhard Nahler4. 1. Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee,Klagenfurt am Wörthersee, Austria. 2. Medical University Graz, Graz, Austria. 3. Neurologische Abteilung, Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria. 4. CIS Clinical Investigation Support GmbH, Vienna, Austria.
Abstract
Background: Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis. Patients and Methods: We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy). Results: Of 15 patients, seven (46.7%) are now living for at least 24 months, and four (26.7%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months). Conclusion: CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme. Copyright 2021, International Institute of Anticancer Research.
Background: Glioblastoma multiforme (GBM) is a relatively rare type of brain tumour with an incidence rate around 6 per 100,000. Even with the widely practiced combination of radiotherapy with adjuvant temozolomide, the median overall survival remains low with just 13.5 to 16 months after diagnosis. Patients and Methods: We retrospectively reviewed the survival of a cohort of 15 consecutive, unselected patients with histopathologically confirmed glioblastoma multiforme (GBM) who received CBD (400 to 600 mg orally per day) in addition to standard therapy (maximum resection of the tumour followed by radio-chemotherapy). Results: Of 15 patients, seven (46.7%) are now living for at least 24 months, and four (26.7%) for at least 36 months. This is more than twice as long as has been previously reported in the literature. The mean overall survival is currently 24.2 months (median 21 months). Conclusion: CBD is a well supported co-medication and seems to prolong the survival of patients with glioblastoma multiforme. Copyright 2021, International Institute of Anticancer Research.
Authors: N Rimmerman; D Ben-Hail; Z Porat; A Juknat; E Kozela; M P Daniels; P S Connelly; E Leishman; H B Bradshaw; V Shoshan-Barmatz; Z Vogel Journal: Cell Death Dis Date: 2013-12-05 Impact factor: 8.469
Authors: Chris Twelves; Michael Sabel; Daniel Checketts; Sharon Miller; Bola Tayo; Maria Jove; Lucy Brazil; Susan C Short Journal: Br J Cancer Date: 2021-02-24 Impact factor: 7.640